Press
Releases
Press Releases
AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that new data from its ongoing, collaborator-sponsored 1 Phase 1/2 clinical trial
May 03, 2022
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 6, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to
Apr 06, 2022
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 5, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Geoff MacKay , president and CEO of AVROBIO , will present at the 21 st Annual
Apr 05, 2022
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
Provided interim data at WORLDSymposium™ 2022 that showed sustained engraftment across first three patients 1 + year post-gene therapy in Phase 1/2 clinical trial i for cystinosis; all remain off oral cysteamine to date Interim clinical data update of AVR-RD-02 in Gaucher disease type 1 planned
Mar 17, 2022
AVROBIO to Present at Two Upcoming Investor Conferences in March
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 1, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two
Mar 01, 2022
AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis
Sustained engraftment observed across first three patients 1+ year post-gene therapy; all remain off oral cysteamine to date Reduction in number of cystine crystals as measured in skin and intestinal mucosa biopsies observed across first three patients Continued favorable safety profile with no
Feb 09, 2022
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 4, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to
Feb 04, 2022
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 1, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced the appointment of Sean O’Bryan as chief regulatory officer.
Feb 01, 2022
AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 28, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO , will present
Jan 28, 2022
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
Analyst and investor conference call scheduled for Wednesday, Feb. 9, 2022 , at 8:00 a.m. ET Five platform presentations and three posters on the company’s clinical and preclinical programs for lysosomal disorders are scheduled throughout the symposium CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan.
Jan 27, 2022
Displaying 11 - 20 of 22